Dicerna Pharmaceuticals (NASDAQ:DRNA) saw an uptick in trading volume on Friday after the company announced better than expected quarterly earnings, American Banking & Market Newsreports. 357,389 shares were traded during mid-day trading, an increase of 103% from the previous session’s volume of 176,045 shares.The stock last traded at $29.05 and had previously closed at $30.61. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares after opening at $29.32 moved to $29.50 on last trade day and at the end of the day closed at $28.25. Company price to sales ratio in past twelve months was calculated as 79.64 and price to cash ratio as 9.17. Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) showed a negative weekly performance of -16.05%.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company’s financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1-866-318-8613 (domestic) or 1-617-399-5132 (international) five minutes prior to the start of the call and providing the passcode 57921892. A replay of the call will be available two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), providing the passcode 61612931. The replay will be available for two weeks from the date of the live call.AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) shares fell -0.99% in last trading session and ended the day on $1.50. AEVO return on equity ratio is recorded as -105.50% and its return on assets is -58.80%. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) yearly performance is -80.20%.
Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, announced financial results for the year ended December 31, 2013, and provided an update on its clinical trials of ThermoDox®, Celsion’s proprietary heat-activated liposomal encapsulation of doxorubicin. ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II clinical trial for recurrent chest wall breast cancer. Celsion Corporation (NASDAQ:CLSN) shares moved down -1.46% in last trading session and was closed at $3.37, while trading in range of $3.31-$3.40. Celsion Corporation (NASDAQ:CLSN) year to date performance is -13.37%.
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company developing, manufacturing and commercializing innovative therapies to address unmet needs in severe burn and wound management, announced the closing of its initial public offering of 5,750,000 ordinary shares at a price to the public of $14.00 per share. All of the shares of common stock in the offering were offered by MediWound and include 750,000 shares issued pursuant to the full exercise of the underwriters’ 30-day option to purchase up to 750,000 additional shares at the initial public offering price. Mediwound Ltd (NASDAQ:MDWD) weekly performance is -15.93%. On last trading day company shares ended up $14.41. Mediwound Ltd (NASDAQ:MDWD) distance from 50-day simple moving average is -12.29%.
Leave a Reply